Roth Capital Maintains Buy On Sucampo Following The Launch Of Amitiza DTC Campaign
In a research report issued today, Roth Capital analyst Ed Arce maintained a Buy rating on Sucampo (NASDAQ:SCMP) with a $9 price target, following the company’s launch of a pilot direct-to-consumer (DTC) campaign for Amitiza, including both TV and print ads.
Arce wrote, “After speaking with management, we learned that this campaign will run for a few months and that Sucampo’s share of the costs have already been recognized in prior financial statements. We anticipate these ads will increase patient-physician dialogue and raise overall awareness of Amitiza, driving accelerating prescription growth.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Ed Arce has a total average return of 8.6% and a 24.1% success rate. Arce has an -9.0% average return when recommending SCMP, and is ranked #948 out of 3309 analysts.